Efficacy of olanzapine and haloperidol in an animal model of mania

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 30, Issue 7, 2006, Pages 1261-1264

  El Mallakh, Rif S ^a   Decker, Sarah ^a   Morris, Matthew ^a   Li, Xiao Ping ^a   Huff, Mary O'Malley ^a   El Masri, M Adnan ^a   Levy, Robert S ^a  

^a University of Louisville School of Medicine   (United States)

Author keywords

Bipolar disorder; Haloperidol; Hyperlocomotion; Na,K ATPase; Olanzapine; Ouabain; Sodium pump

Indexed keywords

HALOPERIDOL DECANOATE; OLANZAPINE; OUABAIN;

ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG MEGADOSE; HYPERACTIVITY; LOW DRUG DOSE; MALE; MANIA; MOTOR ACTIVITY; NONHUMAN; OPEN FIELD BEHAVIOR; RAT; TREATMENT OUTCOME;

ANALYSIS OF VARIANCE; ANIMALS; ANTIPSYCHOTIC AGENTS; BEHAVIOR, ANIMAL; BENZODIAZEPINES; BIPOLAR DISORDER; DISEASE MODELS, ANIMAL; DRUG EVALUATION; DRUG INTERACTIONS; ENZYME INHIBITORS; EXPLORATORY BEHAVIOR; HALOPERIDOL; MALE; OUABAIN; RATS; RATS, SPRAGUE-DAWLEY;

EID: 33747054422     PISSN: 02785846     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2006.04.003     Document Type: Article

References (25)

1. Callaghan J.T., Bergstrom R.F., Ptak L.P., and Beasley Jr. C.M. Olanzapine: pharmacokinetics, pharmacodynamics, and clinical trial profile. Clin Pharmacokinet 37 (1999) 177-193
2. Changaris D.G., Porter J.L., Miller J.J., and Levy R.S. Des-Leu angiotensin I: biosynthesis and drinking response. Regul Pept 20 (1988) 273-280
3. Cooper D.A., Piper D.C., Upton N., and Leslie R.A. The effect of lithium on the hypermotility response to the central administration of ouabain in the rat. Br J Pharmacol 118 (1996) 62P [suppl]
4. Decker S., Grider G., Cobb M., Li X.-P., Huff M.O., El-Mallakh R.S., et al. Open field is more sensitive than automated activity monitor in documenting ouabain-induced hyperlocomotion in the development of an animal model of bipolar illness. Prog Neuro-Psychopharmacol Biol Psychiatry 24 (2000) 455-462
5. El-Mallakh R.S., Harrison L.T., Li R., Changaris D.G., and Levy R.S. An animal model for mania: preliminary results. Prog Neuro-Psychopharmacol Biol Psychiatry 19 (1995) 955-962
6. El-Mallakh R.S., Huff M.O., Li X.-P., Decker S., and Levy R.S. Intracerebroventricular administration of ouabain to rats models mania. Bipolar Disord 5 (2003) 362-365
7. Fowler S.C., and Wang G. Chronic haloperidol produces a time- and dose-related slowing of lick rhythm in rats: implications for rodent models of tardive dyskinesia and neuroleptic-induced parkinsonism. Psychopharmacol (Berl) 137 (1998) 50-60
8. Hillebrand J.J., van Elburg A.A., Kas M.J., van Engeland H., and Adan R.A. Olanzapine reduces physical activity in rats exposed to activity-based anorexia: possible implications for treatment of anorexia nervosa?. Biol Psychiatry 58 (2005) 651-657
9. Kapur S., Vanderspek S.C., Brwonlee B.A., and Nobrega J.N. Antipsychotic dosing in preclinical models is often unrepresentative of the clinical condition: a suggested solution based on in vivo occupancy. J Pharmacol Exp Ther 305 (2003) 625-631
10. Li R., Wing L., Shen Y., Wyatt R.J., Kirch D.G., and Chuang D.-M. Chronic haloperidol treatment attenuates receptor-mediated phosphoinositide turnover in rat brain slices. Neurosci Lett 129 (1991) 81-85
11. Li R., Wing L., Wyatt R.J., and Kirch D.G. Effects of haloperidol, lithium, and valproate on phosphoinositide turnover in rat brain. Pharmacol Biochem Behav 46 (1993) 323-329
12. Looney S.W., and El-Mallakh R.S. Meta-analysis of erythrocyte Na,K-ATPase activity in bipolar illness. Depress Anxiety 5 (1997) 53-65
13. Lorene-Koci E., Wolfarth S., and Ossowska K. Haloperidol-increased muscle tone in rats as a model of parkinsonian rigidity. Exp Brain Res 109 (1996) 268-276
14. McElroy S.L., Keck Jr. P.E., Stanton S.P., Tugrul K.C., Bennett J.A., and Strakowski S.M. A randomized comparison of divalproex oral loading versus haloperidol in the initial treatment of acute psychotic mania. J Clin Psychiatry 57 (1996) 142-146
15. Muzina D.J., and Calabrese J.R. Maintenance therapies in bipolar disorder: focus on randomized controlled trials. Aust N Z J Psychiatry 39 (2005) 652-661
16. Potts B.D. Disposition and biotransformation of olanzapine in animals and humans. In: Tran P.V., Bymaster F.P., Tye N., Herrera J.M., Breier A., and Tollefson G.D. (Eds). Olanzapine (Zyprexa) - a novel antipsychotic (2000), Lippincott Williams and Wilkins, Philadelphia, PA 217-231
17. Rose A.M., Mellet B.J., Valdes Jr. R., Kleinman J.E., Herman M.M., Li R., et al. Alpha2 isoform of the Na,K-adenosine triphosphatase is reduced in temporal cortex of bipolar individuals. Biol Psychiatry 44 (1998) 892-897
18. Ruktanonchai D.J., El-Mallakh R.S., Li R., and Levy R.S. Persistent hyperactivity following a single intracerebroventricular dose of ouabain. Physiol Behav 63 (1998) 403-406
19. Sachs G.S., Grossman R., Ghaemi S.N., Okamoto A., and Bowden C.L. Combination of a mood stabilizer with resperidone or haloperidol for treatment of acute mania: a double-blind, placebo-controlled comparison of efficacy and safety. Am J Psychiatry 159 (2002) 1146-1154
20. Tohen M., Sanger T.M., McElroy S.L., Tollefson G.D., Chengappa K.N.R., Daniel D.G., et al. Olanzapine versus placebo in the treatment of acute mania. Am J Psychiatry 156 (1999) 702-709
21. Tohen M., Jacobs T.G., Grundy S.L., McElroy S.L., Banov M.C., Janicak P.G., et al. Efficacy of olanzapine in acute bipolar mania: a double-blind, placebo-controlled study. The Olanzapine HGGW Study Group. Arch Gen Psychiatry 57 (2000) 841-849
22. Tohen M., Zhang F., Taylor C.C., Burns P., Zarate C., Sanger T., et al. A meta-analysis of the use of typical antipsychotic agents in bipolar disorder. J Affect Disord 65 (2001) 85-93
23. Tohen M., Vieta E., Ketter T., Sachs G., Bowden C., Mitchell P.B., et al. Efficacy of olanzapine and olanzapine-flouxetine combination in the traetment of bipolat I depression. Arch Gen Psychiatry 60 (2003) 1079-1088 (Erratum Arch Gen Psychiatry 2004;61:176)
24. Tohen M., Greil W., Calabrese J.R., Sachs G.S., Yatham L.N., Oerlinghausen B.M., et al. Olanzapine versus lithium in the maintenance treatment of bipolar disorder: a 12-month, randomized, double-blind, controlled clinical trial. Am J Psychiatry 162 (2005) 1281-1290
25. Wang R.Y., Liang X., Jademark K.E., and Arvanov V. Facilitation of NMDA transmission by olanzapine. In: Tran P.V., Bymaster F.P., Tye N., Herrera J.M., Breier A., and Tollefson G.D. (Eds). Olanzapine (Zyprexa) - a novel antipsychotic (2000), Lippincott Williams and Wilkins, Philadelphia, PA 114-131